Circulating tumor markers and nuclear medicine imaging modalities: Breast, prostate and ovarian cancer

Quarterly Journal of Nuclear Medicine

Volumn 46, Issue 2, 2002, Pages 88-104

  Ugrinska, A ^a   Bombardieri, E ^a   Stokkel, M P M ^a   Crippa, F ^a   Pauwels, E K J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast neoplasms, radionuclide imaging; Fludeoxyglucose F18; Ovarian neoplasms, radionuclide imaging; Prostatic neoplasms, radionuclide imaging; Tomography, emission computed; Tumor markers, biological

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CAPROMAB PENDETIDE IN 111; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CYTOKERATIN; FLUORODEOXYGLUCOSE F 18; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; TECHNETIUM PHOSPHATE TC 99M; TUMOR MARKER;

ANALYTICAL PARAMETERS; ANTIBODY SPECIFICITY; BLOOD LEVEL; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COLON ADENOCARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; FOLLOW UP; GERM CELL TUMOR; HUMAN; MAMMOGRAPHY; MEDICAL INFORMATION; METASTASIS; MORPHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; ONCOLOGY; OVARY CANCER; OVARY TUMOR; PATIENT MONITORING; PROSTATE CANCER; PROTEIN DETERMINATION; RELAPSE; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; TESTIS TUMOR; TISSUE SPECIFICITY; TOMOGRAPHY; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036620183     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Tumor markers
2. Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma
3. An update on the biology of mucins as tumor markers
4. GLOBOCAN 2000. Cancer incidence, mortality and prevalence rate worldwide
5. Breast cancer
6. Breast cancer
7. Tumor marker measurements in the diagnosis and monitoring of breast cancer
8. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers. European Group for Serum Tumor Markers in Breast Cancer
9. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients
10. The clinical value of CEA and CA 15-3 in breast cancer management
11. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen
12. Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group
13. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology
14. Breast cancer and clinical utility of CA 15-3 and CEA
15. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
16. Tumor markers in oncology
17. 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis
18. Technical aspects of performing lymphoscintigraphy: Optimization of methods used to obtain images
19. Vital dyes in sentinel node localization
20. The clinical course of bone metastases from breast cancer
21. Reappraisal of the baseline bone scan in breast cancer
22. Skeletal metastases from breast cancer: Imaging with nuclear medicine
23. A changing role for bone scintigraphy in oncology: The road from routine imaging screening to patient-based screening
24. Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques
25. The role of tumor markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy
26. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer
27. CA 15-3 and bone scintigraphy in the follow-up of breast cancer
28. Can tumor marker assays be a guide in the prescription of bone scan for breast and lung cancers?
29. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
30. Bone metabolic markers in bone metastases
31. Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases
32. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
33. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma
34. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer
35. PET imaging in breast cancer
36. 18FDG imaging in breast cancer
37. FDG-PET in imaging of gynaecologic cancer
38. 18F-FDG in oncology
39. Role of positron emission tomography in suspected tumour recurrence when there is increased serum tumor markers
40. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET)
41. Cancer statistics, 1999
42. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate
43. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France
44. Cancer of the prostate: A nutritional disease?
45. Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer
46. Urologic cancers
47. Prostate cancer - Old problems and new approaches. (Part II. Diagnostic and prognostic markers, pathology and biological aspects)
48. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy
49. State-of-the-art staging in prostate cancer
50. Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges
51. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update
52. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer
53. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers
54. 111indium-labelled monoclonal antibody CYT-356
55. Prostate cancer: The contribution of nuclear medicine
56. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy
57. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
58. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer
59. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer
60. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up
61. Correlation between bone metabolic markers and bone scan in prostatic cancer
62. A reappraisal of serial isotope bone scans in prostate cancer
63. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer
64. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
65. PSA and bone scintigraphy
66. Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected on bone scintigraphy in patients with newly diagnosed prostate carcinoma
67. The significance of serum alkaline phosphatase bone isoenzyme in prostatic carcinoma with bony metastasis
68. The diagnostic value of urinary crosslaps and serum alkaline phosphatase in patients with prostate cancer
69. Markers of bone turnover for the management of patients with bone metastases from prostate cancer
70. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen
71. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients
72. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group
73. 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy
74. Cancer statistics
75. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
76. Epidemiology of ovarian cancer: A summary review
77. Ovarian cancer: Epidemiology, biology, and prognostic factors
78. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations
79. Genetic disparity between morphologically benign cyst contiguous to ovarian carcinomas and solitary cystadenomas
80. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials
81. Treatment of ovarian stromal tumors
82. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumors
83. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary
84. Cisplatin-containing regimen in advanced or recurrent granulosa cell tumors of the ovary
85. Current management of ovarian germ cell tumors
86. Reactivity of a monoclonal antibody with human ovarian carcinoma
87. Circulating tumor markers in gynecological tumors
88. Tumor marker trends in asymptomatic women at risk for ocarina cancer: Relevance for ovarian cancer screening
89. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis
90. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer
91. The use of serial complementary tumor markers to improve sensitività and specificità for early detection
92. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
93. Defining progression of ovarian carcinoma durino follow-up according to CA 125: A North Thames Group study
94. Biochemical characteristics and clinical application of α-fetoprotein isoforms
95. Normal biology of α-fetoprotein
96. Clinical features and prognosis of hepatocellular carcinoma with reference to serum α-fetoprotein levels
97. Hepatocellular carcinoma in Italian patients with cirrhosis
98. Prospective study of α-fetoprotein in cirrhotic patients monitorated for development of hepatobellular carcinoma
99. Current approaches to diagnosis and treatment of ovarian germ cell malignancies
100. Consensus statement on circulating tumor markers and staging patients with germ cell tumors
101. HCG in non-gynaecological tumor
102. HCG role in gynaecologic tumors
103. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in non seminomatous germ cell tumors
104. The effectiveness of ovarian cancer screening. A decision analysis model
105. Genetic, biochemical, and multimodal approaches to screening for ovarian cancer
106. Evaluation of CA 125 levels in differentiating malignant from benign tumorsin patients with pelvic masses
107. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors
108. Color Doppler sonography of ovarian masses. A multiparameter analysis
109. Evaluation of clinically suspected adnexal masses
110. Radioimmunoscintigraphy in patients with ovarian cancer
111. Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab′)2: Pharmacokinetics, tissue distribution, and tumor imaging
112. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer
113. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: Correlation with second-look laparotomy
114. 18F-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
115. 2-Fluorine-18-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer
116. Tumor marker in ovarian cancer
117. Clinical uses of tumor markers: A critical review
118. How CA 125 is used in routine clinical practice
119. Follow-up of treated cancers of the ovary
120. Evaluation of the diagnostic usefulness of CA 125 immunoscintigraphy for ovarian carcinoma follow-up after treatment: Contribution of this techniques in Grenoble University Medical Center
121. Impact of radioimmunoscintigraphy on the management of colorectal and ovarian cancer patients: A retrospective study
122. Radioimmunoscintigraphy in patients with ovarian cancer
123. 111In satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis
124. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature
125. Monoclonal antibody MAb-170 for immunoscintigraphy detection of ovarian tumors
126. False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose
127. Effect of circulating antigen on immunoscintigraphy of ovarian cancer patients using anti-CA125 monoclonal antibody
128. 18F-FDG PET) in diagnosis of ovarian cancer
129. Whole-body PET with (fluorite-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report
130. Clinical value of PET with FDG for recurrent ovarian cancer
131. Whole-body PET with FDG for detecting recurrent primary serous peritoneal carcinoma: An initial report
132. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer